Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 2/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.52 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 4/20 | 0.46 |
| ▸ | VNN1 | O95497 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL826127 | 0.98 | PNMT (0.50) | PNMTTAAR1PIK3CAKMT2ALOXL2 | |
| SCHEMBL2814665 | 0.84 | PIK3CA (0.40) | PNMTTAAR1PIK3CALOXL2CA2 | |
| SCHEMBL2791411 | 0.84 | PIK3CA (0.54) | PNMTTAAR1PIK3CATSHRCA2 | |
| SCHEMBL2251905 | 0.82 | PIK3CA (0.51) | PNMTTAAR1PIK3CAKMT2ATSHR | |
| Hydrochloric Acid SCHEMBL1221757 | 0.82 | PIK3CA (0.52) | PNMTTAAR1PIK3CATSHRCA2 | |
| Hydrochloric Acid SCHEMBL1150500 | 0.82 | ANO1 (0.39) | PNMTTAAR1PIK3CALOXL2CA2 | |
| SCHEMBL15930102 | 0.81 | PNMT (0.58) | PNMTTAAR1TSHRIDO1SIGMAR1 | |
| SCHEMBL1351021 | 0.81 | PIK3CA (0.50) | PNMTTAAR1PIK3CAKMT2ATSHR | |
| SCHEMBL8376663 | 0.81 | TSHR (0.50) | PIK3CAKMT2ATSHRCA2IDO1 | |
| SCHEMBL1029174 | 0.80 | SLC6A4 (0.54) | PNMTTAAR1PIK3CAKMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2291377-B1 | IMIDAZOPYRIMIDINONES AND USES THEREOF | AVEXA LTD (AU) | 2015-02-18 | — | — | EP | disclosed |
| US-8859563-B2 | Bicyclic pyrimidinones and uses thereof | AVEXA LIMITED (AU) | 2014-10-14 | — | — | US | disclosed |
| US-8859563-B2 | Bicyclic pyrimidinones and uses thereof | AVEXA LIMITED (AU) | 2014-10-14 | — | — | US | disclosed |
| EP-2759544-A1 | Compounds having antiviral properties | Avexa Limited (AU) | 2014-07-30 | — | — | EP | disclosed |
| EP-2212324-B1 | COMPOUNDS HAVING ANTIVIRAL PROPERTIES | AVEXA LTD (AU) | 2014-03-26 | — | — | EP | disclosed |
| US-8563562-B2 | Compounds having antiviral properties | AVEXA LIMITED (AU) | 2013-10-22 | — | — | US | disclosed |
| US-8431581-B2 | Imidazopyrimidines and uses thereof | AVEXA LIMITED (AU) | 2013-04-30 | — | — | US | disclosed |
| US-8426405-B2 | Thiazopyrimidinones and uses thereof | AVEXA LIMITED (AU) | 2013-04-23 | — | — | US | disclosed |
| EP-2247601-B1 | THIAZOPYRIMIDINONES AND USES THEREOF | AVEXA LTD (AU) | 2013-04-10 | — | — | EP | disclosed |
| US-20130059865-A1 | COMPOUNDS HAVING ANTIVIRAL PROPERTIES | AVEXA LIMITED (AU) | 2013-03-07 | — | — | US | disclosed |
| US-20110009366-A1 | BICYCLIC PYRIMIDINONES AND USES THEREOF | AVEXA LIMITED (AU) | 2011-01-13 | — | — | US | disclosed |
| US-20110009366-A1 | BICYCLIC PYRIMIDINONES AND USES THEREOF | AVEXA LIMITED (AU) | 2011-01-13 | — | — | US | disclosed |
| EP-2269992-A1 | Bicyclic pyrimidinones for the treatment of viral infections | Avexa Limited (AU) | 2011-01-05 | — | — | EP | disclosed |
| EP-2247601-A1 | THIAZOPYRIMIDINONES AND USES THEREOF | Avexa Limited (AU) | 2010-11-10 | — | — | EP | disclosed |
| EP-2212324-A1 | COMPOUNDS HAVING ANTIVIRAL PROPERTIES | Avexa Limited (AU) | 2010-08-04 | — | — | EP | disclosed |
| US-20100168063-A1 | BICYCLIC PYRIMIDINONES AND USES THEREOF | AVEXA LIMITED (AU) | 2010-07-01 | — | — | US | disclosed |
| US-20100168063-A1 | BICYCLIC PYRIMIDINONES AND USES THEREOF | AVEXA LIMITED (AU) | 2010-07-01 | — | — | US | disclosed |
| WO-2010000032-A1 | COMPOUNDS HAVING ANTIVIRAL PROPERTIES | AVEXA LIMITED (AU) | 2010-01-07 | — | — | WO | disclosed |
| WO-2010000030-A1 | THIAZOPYRIMIDINONES AND USES THEREOF | AVEXA LIMITED (AU) | 2010-01-07 | — | — | WO | disclosed |
| WO-2008077188-A1 | BICYCLIC PYRIMIDINONES AND USES THEREOF | AVEXA LIMITED (AU) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168063-A1 | BICYCLIC PYRIMIDINONES AND USES THEREOF | TPMT, TYMP, DPYD | PNMT 2036/4885TAAR1 2531/4885PIK3CA 983/4885 |
| US-20110009366-A1 | BICYCLIC PYRIMIDINONES AND USES THEREOF | TPMT, TYMP, DPYD | PNMT 2036/4885TAAR1 2531/4885PIK3CA 983/4885 |
| US-20130059865-A1 | COMPOUNDS HAVING ANTIVIRAL PROPERTIES | ZC3HAV1, ACE, EIF2AK2 | PNMT 3784/4885TAAR1 4137/4885PIK3CA 1718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.